TITLE

Rosiglitazone increased heart failure but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis

PUB. DATE
November 2007
SOURCE
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a clinical study investigating the effectiveness level of rosiglitazone (RGZ) over metformin (MFN) and sulfonylurea (SFU), as an add-on therapy of cardiovascular (CV) diseases. It discusses the procedure followed along with the randomized controlled trial (RCT), carried out during the study. It mentions that the study revealed an increase in the risk of heart failure due to RGZ, but no difference was found between RGZ and MFN plus CFU, for other CV outcomes.
ACCESSION #
28019873

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics